Projections are for massive increase in prescribing of oral MS agents at the expense of injectable market share, with about a 50/50 split by the time contract runs out on Rebif. With future revenue collapsing at that point and into the future, can't see any further involvement with the product. The golden days of Rebif for Pfizer (and there were some) are gone. Have a plan.